Middle East Healthcare Company
Middle East Healthcare Company (4009.SR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
4009.sr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Middle East Healthcare Company (4009.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4009.SR's current PE ratio of 18.09x is calculated by dividing its stock price of $33.00 by its TTM earnings per share of $1.82. −74.7% discount vs 5Y avg 71.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 14 fiscal years · Front-end computedMinQ1 · 25%25.2x
MedianQ3 · 75%248.3x
Max
At 18.09x, 4009.SR's current P/E is within its average historical range over the past 14 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Middle East Healthcare CompanyYou 4009.SR | $3.0B | 18.09x | -24.9% | $1.82 |
 Saudi Pharmaceutical Industries and Medical Appliances Corporation 2070.SR | $3.4B | 16.92x | -29.7% | $1.54 |
 National Medical Care Company 4005.SR | $4.8B | 20.01x | -16.9% | $7.13 |
 Al Hammadi Holding Company 4007.SR | $4.5B | 18.53x | -23.0% | $1.51 |
 Middle East Pharmaceutical Industries Company 4016.SR | $2.2B | 22.93x | -4.7% | $2.77 |
 Al-Dawaa Medical Services Company 4163.SR | $3.7B | 13.17x | -45.3% | $3.79 |
 Canadian General Medical Center Complex Company 9518.SR | $697M | 52.86x | +119.6% | $0.13 |
Industry Average 6 peers with valid PE | — | 24.07x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 9.93x | $3.28 | -55.7% | |
2024-12-31 FY2024 | 22.42x | $3.06 | -50.3% | |
2023-12-31 FY2023 | 45.11x | $1.96 | +43.1% | |
2022-12-31 FY2022 | 31.52x | $0.82 | -87.3% | |
2021-12-31 FY2021 | 248.29x | $0.13 | +531.1% | |
2020-12-31 FY2020 | 39.35x | $0.89 | +40.4% | |
2019-12-31 FY2019 | 28.02x | $1.06 | +61.6% | |
2018-12-31 FY2018 | 17.34x | $1.87 | +5.0% | |
2017-12-31 FY2017 | 16.52x | $3.26 | -11.4% | |
2016-12-31 FY2016 | 18.65x | $3.93 | +12.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Middle East Healthcare Company (4009.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4009.SR's current PE ratio of 18.09x is calculated by dividing its stock price of $33.00 by its TTM earnings per share of $1.82.
Frequently asked questions
4009.SR pe ratio · 6 questions4009.SR's current PE ratio is 18.09x as of 2026-06-15, based on a stock price of $33.00 and TTM EPS of $1.82. Data sourced from Financial Modeling Prep via 4009.SR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Middle East Healthcare Company SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-15